Friday, 16 October 2026European Markets

INCLUSIO SA/NV And BASSAC Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - inclusio sa/nv (inclu.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
inclusio sa/nv (inclu.br) €15.55 5.07% 16.11%
bassac (bass.pa) €41.60 3.37% 6.27%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. inclusio sa/nv (inclu.br)

5.07% forward dividend yield and 16.11% return on equity

inclusio sa operates as a real estate company in belgium. it focuses on affordable rental housing, housing for disabled, and social infrastructures. inclusio sa was incorporated in 2011 and is based in brussels, belgium.

earnings per share

as for profitability, inclusio sa/nv has a trailing twelve months eps of €4.5.

pe ratio

inclusio sa/nv has a trailing twelve months price to earnings ratio of 3.46. meaning, the purchaser of the share is investing €3.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.11%.

volume

today's last reported volume for inclusio sa/nv is 1369 which is 34.9% below its average volume of 2103.

moving average

inclusio sa/nv's value is higher than its 50-day moving average of €14.56 and way higher than its 200-day moving average of €13.65.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 22, 2024, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 5.07%.

more news about inclusio sa/nv.

2. bassac (bass.pa)

3.37% forward dividend yield and 6.27% return on equity

bassac société anonyme operates as a real estate development company primarily in france, belgium, germany, and spain. it offers residential buildings and houses, and commercial real estate, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €5.81.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 7.16. meaning, the purchaser of the share is investing €7.16 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.27%.

moving average

bassac's worth is below its 50-day moving average of €42.55 and under its 200-day moving average of €44.70.

volume

today's last reported volume for bassac is 1487 which is 96.43% above its average volume of 757.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 21, 2024, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 3.37%.

more news about bassac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com